

Jean-Pierre Delord

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1103485/publications.pdf>

Version: 2024-02-01

146
papers

11,563
citations

61945

43
h-index

30058

103
g-index

152
all docs

152
docs citations

152
times ranked

17922
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	0.8	1,740
2	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	7.7	1,033
3	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1324-1334.	5.1	897
4	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1470-1478.	0.8	671
5	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
6	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	0.8	345
7	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. <i>Cancer Discovery</i> , 2016, 6, 492-500.	7.7	319
8	CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 949-956.	5.1	298
9	Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2825-2834.	0.8	280
10	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2804-2811.	3.2	249
11	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	3.4	235
12	Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death. <i>International Journal of Molecular Sciences</i> , 2012, 13, 9545-9571.	1.8	228
13	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3415-3420.	0.8	217
14	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	7.7	206
15	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2017, 7, 610-619.	7.7	194
16	Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3007-3014.	0.8	184
17	Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 17-39.	2.7	156
18	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1083-1088.	0.6	145

#	ARTICLE	IF	CITATIONS
19	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5339-5348.	3.2	142
20	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	3.2	132
21	Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). <i>Cancer Research</i> , 2015, 75, 2859-2859.	0.4	128
22	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	3.4	127
23	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. <i>Journal of Clinical Oncology</i> , 2017, 35, 3071-3071.	0.8	107
24	Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). <i>Cancer Research</i> , 2017, 77, CT074-CT074.	0.4	106
25	Vinflunine: A New Microtubule Inhibitor Agent. <i>Clinical Cancer Research</i> , 2008, 14, 1625-1632.	3.2	104
26	A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. <i>European Journal of Cancer</i> , 2017, 76, 110-117.	1.3	89
27	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. <i>Cancer Research</i> , 2017, 77, 2986-2986.	0.4	89
28	Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. <i>Melanoma Research</i> , 2017, 27, 485-491.	0.6	88
29	In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 709-718.	1.1	86
30	HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand-Foot Syndrome. <i>Oncologist</i> , 2011, 16, 1469-1478.	1.9	82
31	Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 3783-3790.	0.8	76
32	Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2016, 17, 391-397.	1.1	75
33	Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 7086-7092.	3.2	68
34	Toxicity patterns of cytotoxic drugs. <i>Investigational New Drugs</i> , 2003, 21, 141-148.	1.2	67
35	PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. <i>JCI Insight</i> , 2021, 6, .	2.3	64
36	Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. <i>Cancer Research</i> , 2014, 74, CT326-CT326.	0.4	62

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.. Journal of Clinical Oncology, 2018, 36, 5522-5522.	0.8	59
38	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Targeted Oncology, 2012, 7, 253-265.	1.7	57
39	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY" phase 1-2 trial. Oncotarget, 2015, 6, 12796-12808.	0.8	56
40	Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU. Oncologist, 2010, 15, 212-213.	1.9	55
41	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research, 2021, 27, 1037-1047.	3.2	55
42	Formation of the eIF4F Translation Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors. Cancer Research, 2011, 71, 4068-4073.	0.4	49
43	Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. Journal of Molecular Cell Biology, 2020, 12, 202-215.	1.5	47
44	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research, 2021, 27, 3360-3369.	3.2	47
45	Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. Cancer Research, 2018, 78, CT180-CT180.	0.4	44
46	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 8503-8503.	0.8	43
47	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clinical Cancer Research, 2015, 21, 2753-2762.	3.2	42
48	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced "Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 556-566.	0.5	40
49	Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. BMC Cancer, 2019, 19, 167.	1.1	39
50	Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEK Prospective Study. Clinical Chemistry, 2019, 65, 1267-1275.	1.5	38
51	MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, 2579-2579.	0.8	38
52	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer, 2015, 15, 700.	1.1	37
53	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. , 2020, 8, e001153.		37
54	Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children. Clinical Cancer Research, 2011, 17, 4862-4871.	3.2	35

#	ARTICLE	IF	CITATIONS
55	Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. <i>Melanoma Research</i> , 2015, 25, 555-558.	0.6	35
56	Population pharmacokinetics of oxaliplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 127-131.	1.1	33
57	Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2013, 31, 1207-1216.	1.2	32
58	Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine. <i>Clinical Cancer Research</i> , 2005, 11, 3038-3044.	3.2	31
59	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
60	Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. <i>Clinical Colorectal Cancer</i> , 2012, 11, 38-44.	1.0	29
61	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. <i>European Journal of Cancer</i> , 2020, 141, 162-170.	1.3	29
62	Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3005-3005.	0.8	28
63	A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2511-2511.	0.8	28
64	Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4434-4445.	3.2	27
65	Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8034-8034.	0.8	27
66	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , 2010, 28, 76-82.	1.2	26
67	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 496-505.	1.3	26
68	Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2015, 75, PD1-6-PD1-6.	0.4	25
69	An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6025-6025.	0.8	25
70	Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 397-408.	3.3	22
71	Anti-TNF, a magic bullet in cancer immunotherapy?. , 2019, 7, 303.		21
72	A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 900-909.	1.2	20

#	ARTICLE	IF	CITATIONS
73	Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. <i>Journal of Ovarian Research</i> , 2014, 7, 40.	1.3	20
74	A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 138-147.	1.2	20
75	Guideline sheets on the side effects of anticancer drugs are useful for general practitioners. <i>Supportive Care in Cancer</i> , 2015, 23, 3473-3480.	1.0	19
76	Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study. <i>Clinical Lung Cancer</i> , 2018, 19, e277-e285.	1.1	19
77	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1357-1366.	1.1	19
78	Pancreatic cancer intrinsic PI3K activity accelerates metastasis and rewires macrophage component. <i>EMBO Molecular Medicine</i> , 2021, 13, e13502.	3.3	19
79	Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. <i>European Journal of Cancer</i> , 2022, 171, 259-268.	1.3	19
80	Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-190.	0.8	18
81	Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 225-233.	1.0	17
82	F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer. <i>Cancer Letters</i> , 2016, 370, 10-18.	3.2	17
83	Comparison of variable selection methods for high-dimensional survival data with competing events. <i>Computers in Biology and Medicine</i> , 2017, 91, 159-167.	3.9	17
84	Circulating CD14 ^{high} CD16 ^{low} intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. <i>Cancer Research</i> , 2020, 80, e000472.		17
85	Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies. <i>Cancer Research</i> , 2019, 79, CT073-CT073.	0.4	17
86	Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB). <i>Journal of Clinical Oncology</i> , 2016, 34, e14123-e14123.	0.8	17
87	First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 674-683.	1.2	16
88	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. <i>Cancer Immunology Research</i> , 2020, 8, 869-882.	1.6	16
89	Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression. <i>Cancer Research</i> , 2017, 77, CT106-CT106.	0.4	16
90	Improving communication between the general practitioner and the oncologist: a key role in coordinating care for patients suffering from cancer. <i>BMC Cancer</i> , 2020, 20, 495.	1.1	15

#	ARTICLE	IF	CITATIONS
91	Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. <i>Anticancer Research</i> , 2011, 31, 359-66.	0.5	15
92	First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 240-247.	1.3	14
93	Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2020, 26, 6429-6436.	3.2	14
94	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020, 38, 1774-1783.	1.2	13
95	Primary care physicians and oncologists are partners in cancer announcement. <i>Supportive Care in Cancer</i> , 2016, 24, 2473-2479.	1.0	12
96	Definitive radiochemotherapy or initial surgery for oropharyngeal cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 496-503.	1.0	12
97	Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).. , 2013, , .		11
98	Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 979-986.	1.1	10
99	Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors.. <i>Molecular Cancer Therapeutics</i> , 2013, 12, A72-A72.	1.9	10
100	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	3.2	10
101	Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. <i>Investigational New Drugs</i> , 2019, 37, 693-701.	1.2	9
102	Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment. <i>SpringerPlus</i> , 2013, 2, 679.	1.2	8
103	Development of Photoonycholysis with Vandetanib Therapy. <i>Skin Appendage Disorders</i> , 2016, 2, 146-151.	0.5	8
104	Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology. <i>European Journal of Cancer</i> , 2018, 103, 120-126.	1.3	8
105	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	1.7	8
106	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. <i>Targeted Oncology</i> , 2021, 16, 47-57.	1.7	8
107	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. <i>British Journal of Cancer</i> , 2018, 118, 344-352.	2.9	7
108	Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6017-6017.	0.8	7

#	ARTICLE	IF	CITATIONS
109	Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).. Journal of Clinical Oncology, 2014, 32, 10504-10504.	0.8	6
110	Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. Head and Neck, 2013, 35, 809-818.	0.9	5
111	The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer. Clinical and Translational Radiation Oncology, 2019, 16, 34-39.	0.9	5
112	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology, 2021, 16, 37-46.	1.7	5
113	Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.. Journal of Clinical Oncology, 2018, 36, TPS6094-TPS6094.	0.8	5
114	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 166-166.	0.8	5
115	Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer. Current Clinical Pharmacology, 2011, 6, 274-279.	0.2	4
116	Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the β -specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. Cancer Research, 2015, 75, CT136-CT136.	0.4	4
117	Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma. , 2018, , .		4
118	PREDICTOR (UNICANCER GEP11): Randomized phase II study of preoperative afatinib in untreated head and neck squamous cell carcinoma (HNSCC) patients.. Journal of Clinical Oncology, 2017, 35, 6021-6021.	0.8	4
119	Drugs and Cancer: an Analysis of the French Pharmacovigilance Database. Therapie, 2013, 68, 149-154.	0.6	3
120	A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.. Journal of Clinical Oncology, 2018, 36, 5542-5542.	0.8	3
121	Emerging new anticancer therapies in 2013. Current Opinion in Oncology, 2014, 26, 357-362.	1.1	2
122	Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. European Journal of Cancer, 2017, 85, 39-48.	1.3	2
123	SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer "Overall survival (OS) analysis.. Journal of Clinical Oncology, 2017, 35, 11515-11515.	0.8	2
124	Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation. Cancer Chemotherapy and Pharmacology, 2006, 58, 189-194.	1.1	1
125	Abstract 4079: EVT801: a selective VEGFR3 inhibitor with the potential for combination with immune-checkpoint therapies, preclinical evidences and plans for first-in-human evaluation. , 2019, , .		1
126	SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer "PFS ratio from patients who crossed-over.. Journal of Clinical Oncology, 2016, 34, 2535-2535.	0.8	1

#	ARTICLE	IF	CITATIONS
127	A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).. Journal of Clinical Oncology, 2014, 32, TPS6097-TPS6097.	0.8	1
128	A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, TPS2604-TPS2604.	0.8	1
129	Abstract 2700: The IAP inhibitor Debio 1143 reverses carboplatin resistance in ovarian cancer cells by inducing both apoptosis and necroptosis. , 2015, , .		1
130	Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors. Pharmaceutical Medicine, 2016, 30, 49-55.	1.0	0
131	Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. JCO Precision Oncology, 2018, 2, 1-11.	1.5	0
132	Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Investigational New Drugs, 2018, 36, 1044-1059.	1.2	0
133	Immune checkpoint inhibitors: a potential treatment breakthrough for metastatic triple-negative breast cancer?. Women's Health Investigation, 2019, 2, 2-2.	0.0	0
134	Abstract 725: eIF4E/4eBP-1 as predictive factor(s) of response to EGFR targeted drug in head and neck cancer. , 2012, , .		0
135	Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.. Journal of Clinical Oncology, 2013, 31, 379-379.	0.8	0
136	Abstract LB-171: Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial.. , 2013, , .		0
137	Abstract A68: Activity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR+) breast cancer cell lines and patients (pts) with genetically characterized HR+ breast cancer in a Phase I clinical trial.. , 2013, , .		0
138	Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2550-2550.	0.8	0
139	Phase I dose-escalation study of an oral administration of the pan-histone deacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2575-2575.	0.8	0
140	Predictor: Randomized phase II study of preoperative afatinib in untreated nonmetastatic head and neck squamous cell carcinoma patients (HNSCC) aiming at identifying predictive and pharmacodynamic biomarkers of efficacy.. Journal of Clinical Oncology, 2014, 32, TPS6105-TPS6105.	0.8	0
141	Abstract 2940: Comprehensive biomarker program demonstrates proof of mechanism and modulation of the tumor microenvironment due to RG7155, a novel therapeutic antibody targeting tumor associated macrophages. , 2014, , .		0
142	Abstract PR04: Targeting tumor-associated macrophages with a novel anti-CSF1R antibody in cancer patients. , 2015, , .		0
143	Could tumor growth rate provide useful information to predict the efficacy of eribulin?. Journal of Clinical Oncology, 2015, 33, e12028-e12028.	0.8	0
144	Abstract 2428: Translational study of F14512, a novel vectorised epipodophyllotoxin, which demonstrates a marked activity on ovarian cancer models from patients. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
145	First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).. Journal of Clinical Oncology, 2019, 37, 2521-2521	0.8	0
146	Abstract 5001: Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck. , 2019, , .		0